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Dear Editor, 
 
The treatment of cancer has been revolutionised by the introduction of targeted agents in the 
last two decades. A targeted agent aims at a particular target   on the cancer cells and 
interferes with the growth and progression of cancer. Broadly, these agents can be of two types: 
inhibitors of small molecules involved in cancer growth (kinases) or monoclonal antibodies which 
target a specific antigen in the cancer cells. These agents have a well established role in the 
management of various solid organ cancers as well as lymphomas and leukemias. The unique 
mode of action allows them to express a different profile of toxicities which are comparatively 
better tolerated than chemotherapy and hence provide a better quality of life (QOL). 
Since the introduction of Rituximab in 1997 for the treatment of non-Hodgkin’s lymphoma and 
Trastuzumab in 1998 for breast cancer, a large number of these agents have been added to the 
armamentarium [1, 2]. The evolving era of targeted agents supplanted the traditional cytotoxic 
agents clearly in terms of overall survival as in the case of trastuzumab for breast cancer and 
imatinib and other tyrosine kinase inhibitors for chronic myeloid leukemia (CML) [3, 4]. Another 
advantage over the conventional chemotherapy was demonstrated in the form of rapidity of 
response to treatment and improved QOL. Improved QOL was the result of oral administration 
of many of these agents thus avoiding frequent hospitalisation and better tolerated toxicity 
profile. The classical example is of erlotinib in adenocarcinoma lung and imatinib in CML. 
Hypersensitivity reactions though uncommon, were characteristics adverse events associated 
with monoclonal antibodies. However, recently developed agents contain an increased proportion 
of human components thus minimising these events. 
As more agents are in pipeline, it will not be a surprise when a targeted agent for every cancer 
will be available. High cost of treatment, cost-effectiveness and marginal benefits at the cost of 
added toxicity are two main issues which need to be addressed comprehensively. Targeted 
therapy is much costlier as compared to conventional chemotherapy. In an economically 
backward country like India, very few cancer patients are actually able to bear the burden of 
targeted therapy. A robust health reform is required in order to provide the benefit of targeted 
therapy to poor patients without crippling the health care system simultaneously. 
Targeted agents must be used judiciously: only when the target is available. A survival benefit of 
a few days to weeks carries no meaning when cost is a big concern. Similarly, a marginal survival 
benefit with the added toxicity of targeted agents must be taken care of. Patients with poor 
performance status and a very short life expectancy (extreme old age) should be given best 
supportive care [5, 6]. 
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